Navigation Links
SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange
Date:12/22/2010

s' equity of less than $4 million and losses from continuing operations and net losses in three of its four most recent fiscal years.

SCOLR was also notified that it did not meet the continued listing standard set forth in Section 1003(a)(iv) of the Company Guide because it had sustained losses which were so substantial in relation to its overall operations or its existing financial resources, or its financial condition had become so impaired that it appeared questionable as to whether SCOLR would be able to continue operations and/or meet its obligations as they mature. On April 13, 2010, SCOLR received notice from the Exchange that it had resolved the continued listing deficiency with respect to Section 1003(a)(iv) of the Company Guide.

As permitted by Exchange rules, SCOLR submitted a plan of compliance on July 28, 2009, that, together with subsequent supplements, advises the Exchange of action SCOLR had taken and intends to take to regain compliance with the continued listing standards. The Exchange accepted this plan of Compliance and granted SCOLR an extension period within which to regain compliance.  The extension period is scheduled to expire on December 27, 2010.

About SCOLR Pharma:

Based in Bothell,  Washington,  SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented CDT platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425-368-1050 or visit http://www.scolr.com/ .

Cautionary Note Regarding Forward Looking Statements:

This press release contains forward-look
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
2. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
3. SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results
4. SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards
5. SCOLR Pharma, Inc. Licenses Dietary Supplements
6. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
7. SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products
8. SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director
9. SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results
10. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
11. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... DIEGO , July 31, 2014  Sorrento Therapeutics, Inc. ... of Mr. Amar Singh , Chief Business Officer and ... apparent natural causes on July 30. "Sorrento is ... friend and colleague. Our immediate thoughts go to Amar,s family ... and Chief Executive Officer. Mr. Singh joined ...
(Date:7/31/2014)... -- ResMed Inc. (NYSE: RMD ) today announced results ... June 30, 2014.  Revenue for the quarter was $415.2 million, ... 1 percent decrease on a constant currency basis). Net income ... the quarter ended June 30, 2013. Diluted earnings per share ... compared to the quarter ended June 30, 2013.  ...
(Date:7/31/2014)... Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC ) today ... June 30, 2014. Financial Results for the Six ... revenue for the quarter ended June 30, 2014 increased to ... 30, 2013 primarily due to IMBRUVICA ® (ibrutinib) net ... for the six months ended June 30, 2014 increased to ...
Breaking Medicine Technology:Sorrento Announces the Unexpected Death of its Chief Business Officer 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23
... 2011 Abaxis, Inc. (NasdaqGS: ABAX), a medical products company ... to discuss its financial results for the second quarter of ... be at 4:15 p.m. ET on Tuesday, October 25, 2011. ... of fiscal year 2012 after the market closes on Tuesday, ...
... Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), a specialty ... on Monday, October 31, 2011 before the opening of the ... call that day at 10:00 a.m. ET to discuss results ... to be used during the call will be available on ...
Cached Medicine Technology:Abaxis to Report Second Quarter Fiscal Year 2012 Financial Results Tuesday, October 25, 2011 2Auxilium Pharmaceuticals to Announce Third Quarter 2011 Results and Conduct Conference Call on Monday, October 31, 2011 2Auxilium Pharmaceuticals to Announce Third Quarter 2011 Results and Conduct Conference Call on Monday, October 31, 2011 3
(Date:8/1/2014)... AAGL, a premiere professional educational society ... to announce a joint venture with several other ... which strongly recommends every hospital teaching endoscopic surgery ... lab for training in an effort to improve ... Endoscopy is the use of small tubular instruments ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Stress management can ... that require hours of concentration and diminish rest and leisure ... damage. It is critical to find a way to manage ... quality of life. , “Having a good sense of work-life ... Adam Jacobs, founding clinician of SF Custom Chiropractic. ...
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 ... updates important developments about chemical listings, appellate decisions, ... proposals that may affect compliance with California's Proposition ... reference to the law, regulations, history and trends ... is the fourth installment of the series which ...
(Date:7/31/2014)... On October 10, at the ... Mesothelioma Applied Research Foundation, in collaboration with the ... regional mesothelioma conference geared to patients ... related to mesothelioma and presented by local and ... will include imaging, genetics, first-line therapies, surgery, chemotherapy, ...
(Date:7/31/2014)... IN (PRWEB) July 31, 2014 In today’s ... increasingly difficult to get. Snoring and sleep apnea (a medical ... rob people and their bed partners of the rest they ... 45% of the population snores and 20 million people in ... 10% have been diagnosed and treated; and of those treated, ...
Breaking Medicine News(10 mins):Health News:AAGL Announces It Has Joined With Other Medical Societies to Encourage Hospitals Teaching Endoscopic Surgery to Establish Simulator Labs for Training 2Health News:SF Custom Chiropractic Celebrates National Relaxation Day and the Benefits of Massage Therapy for the Month of August 2Health News:Save 25% on the Proposition 65 Handbook - 2013 Edition Through August 31 2Health News:October Events: Regional Conference on Mesothelioma in Chicago 2Health News:October Events: Regional Conference on Mesothelioma in Chicago 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... seeks insights into chronic, illnesses, including heart failure and COPD, ... ... VENTURA, Calif., Oct. 8 VivoMetrics announced today,that noted researcher Bruce D. ... VivoMetrics LifeShirt(R) System to,the South Pole to collect valuable data for his ...
... Oct. 8 NPS Pharmaceuticals,Inc. (Nasdaq: NPSP ... as,senior vice president and chief commercial officer, effective ... NPS executive team, Mr. O,Callaghan will be,responsible for ... activities, including the commercial development of NPS,s,late-stage products ...
... The Physicians Coalition,for Injectable Safety today issued ... lipolysis or other injectable treatments touted to,reduce localized ... not,be mistaken as an accepted medical or cosmetic ... fat, using compounded pharmaceuticals, or,herbal agents, claim a ...
... the stories of eight mothers who survived ... breast ... product and baby gear brand, celebrates the "Power of Pink" by,announcing the ... Month, the eight outstanding women will be recognized,during the Susan G. Komen ...
... NEW YORK, Oct. 8 Health Management Systems,Inc. ... business of Peer Review,Systems, Inc. d/b/a/ Permedion, an ... in Westerville, Ohio. With this,acquisition, HMS augments its ... offerings for state Medicaid agencies and,managed care organizations. ...
... likely than whites to get tamoxifen, for example , , MONDAY, ... that has spread to the lymph nodes are less likely ... chemotherapy than white women with the same level of disease ... to the lymph nodes, we are seeing that African-American women ...
Cached Medicine News:Health News:VivoMetrics' LifeShirt Going to South Pole to Uncover Clues to High-Altitude Illness 2Health News:VivoMetrics' LifeShirt Going to South Pole to Uncover Clues to High-Altitude Illness 3Health News:NPS Pharmaceuticals Names Brian O'Callaghan as New Chief Commercial Officer 2Health News:Consumer Safety Alert on Fat Dissolving Injections 2Health News:Consumer Safety Alert on Fat Dissolving Injections 3Health News:'Pink Power Moms' Unite in Atlanta for Day of Pampering and Recognition 2Health News:'Pink Power Moms' Unite in Atlanta for Day of Pampering and Recognition 3Health News:'Pink Power Moms' Unite in Atlanta for Day of Pampering and Recognition 4Health News:HMS Acquires Permedion to Expand Clinical Review Capabilities 2Health News:Black Women Get Less Breast Cancer Treatment 2Health News:Black Women Get Less Breast Cancer Treatment 3
... The Research pro Electronic Pipette is ideal ... laboratory. Its easy-to-follow display, ergonomically-placed operating buttons, ... dispensing, reverse pipetting and diluting make this ... simple functions of a manual pipette without ...
... Comfort Pick one of our pipettors up ... trigger and ejector positionsright where they should beeven ... ergonomically designed to help avoid repetitive stress injuries ... In The Palm Of Your Hand Start ...
... for Unparalleled Comfort Pick one of our ... Notice the trigger and ejector positionsright where they ... pipettors are ergonomically designed to help avoid repetitive ... Productivity In The Palm Of Your Hand ...
... The Finnpipette BioControl multichannel ... features as the single ... handle fits all seven ... channel tip cone modules. ...
Medicine Products: